US Optic Nerve Glioma Market

ID: MRFR/Pharma/17481-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Optic Nerve Glioma Market Research Report By Type (malignant optic nerve glioma, benign optic nerve glioma), By Diagnosis (neurological exam, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), biopsy, others), By Treatment (surgery, radiation therapy, chemotherapy, others) and By End User (hospitals & clinics, diagnostic centers, others) - Growth & Industry Forecast 2025 To 2035
US Optic Nerve Glioma Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.87%
2024 Market Size$ 160 Million
2025 Market Size$ 167.79 Million
2035 Market Size$ 270 Million
Key Players
Novartis
Bristol-Myers Squibb
Roche
Merck & Co
Amgen
Eli Lilly and Company
Trends
  • Advancements in Diagnostic Techniques
  • Emergence of Targeted Therapies
  • Increased Focus on Multidisciplinary Care
Opportunities
  • Increased Research Funding
  • Growing Awareness and Advocacy
  • Technological Innovations in Treatment
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Type (USD Million)
      1. 4.1.1 Pilocytic Astrocytoma
      2. 4.1.2 Diffuse Astrocytoma
      3. 4.1.3 Anaplastic Astrocytoma
      4. 4.1.4 Giant Cell Astrocytoma
    2. 4.2 Security, Access Control and Robotics, BY Diagnosis Method (USD Million)
      1. 4.2.1 MRI
      2. 4.2.2 CT Scan
      3. 4.2.3 Biopsy
      4. 4.2.4 Visual Field Testing
    3. 4.3 Security, Access Control and Robotics, BY Treatment (USD Million)
      1. 4.3.1 Surgery
      2. 4.3.2 Radiation Therapy
      3. 4.3.3 Chemotherapy
      4. 4.3.4 Targeted Therapy
    4. 4.4 Security, Access Control and Robotics, BY Patient Age Group (USD Million)
      1. 4.4.1 Children
      2. 4.4.2 Adults
      3. 4.4.3 Elderly
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Merck & Co (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Amgen (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly and Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Pfizer (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Sanofi (FR)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    4. 6.4 US MARKET ANALYSIS BY TREATMENT
    5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
    6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE)
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 (% SHARE)
    17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 TO 2035 (USD Million)
    18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PATIENT AGE GROUP, 2024 (% SHARE)
    19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Optic Nerve Glioma Market Segmentation

US Optic Nerve Glioma Market By Type (USD Million, 2025-2035)

  • Pilocytic Astrocytoma
  • Diffuse Astrocytoma
  • Anaplastic Astrocytoma
  • Giant Cell Astrocytoma

US Optic Nerve Glioma Market By Diagnosis Method (USD Million, 2025-2035)

  • MRI
  • CT Scan
  • Biopsy
  • Visual Field Testing

US Optic Nerve Glioma Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy

US Optic Nerve Glioma Market By Patient Age Group (USD Million, 2025-2035)

  • Children
  • Adults
  • Elderly

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.